News

October 8, 2020October 8, 2020

Phase 1 Trial Finishes Dosing 1st AML Patient Group With Actimab-A Plus Venclexta

News

The first group of patients with relapsed or refractory acute myeloid leukemia (AML) has been dosed in a Phase 1/2 dose-escalation trial assessing the safety and efficacy of Actimab-A and Venclexta (venetoclax) ... Read more

October 1, 2020October 1, 2020

‘Find the Right Fit’ Aims to Educate, Support People With Secondary AML

News

Jazz Pharmaceuticals, with help from the Myelodysplastic Syndrome (MDS) Foundation and the Cancer Support Community, has launched Find the Right Fit, an initiative providing educational resources about MDS and secondary ... Read more

September 28, 2020September 28, 2020

First Clinical Trial Launched for AML, Other Blood Cancer Patients With COVID-19

News

The Leukemia & Lymphoma Society (LLS) has announced the launch of the first clinical trial dedicated to people with blood cancers, including acute myeloid leukemia (AML), who are infected with COVID-19. The study ... Read more

September 24, 2020September 24, 2020

Dosing Begins in Phase 1 Trial Testing Immune-Onc’s IO-202 for Advanced AML, CMML

News

The first patient has been dosed in Immune-Onc Therapeutic’s Phase 1 clinical trial of IO-202, its lead antibody treatment candidate for advanced acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML). The trial (NCT04372433), underway ... Read more

September 21, 2020September 21, 2020

Rigosertib Combo Fails to Prolong Survival in Higher-risk Myelodysplastic Syndromes

News

When given alongside best supportive care, rigosertib failed to prolong the survival of patients with higher-risk myelodysplastic syndromes (HR-MDS), a group of blood cancers that often progress to acute myeloid ... Read more

September 17, 2020September 17, 2020

FDA Grants Rare Pediatric Disease Status to AML Therapy OXi-4503

News

The U.S. Food and Drug Administration (FDA) has granted its Rare Pediatric Disease designation to Mateon Therapeutics’ OXi-4503 (combretastatin A1-diphosphate, CA1P) for the treatment of children and teens with acute ... Read more

September 14, 2020September 14, 2020

French Authorities Advance Phase 3 Trial Testing Sellas’ GPS Cancer Vaccine

News

French regulatory authorities have approved an investigational medicinal product dossier (IMPD) from Sellas Life Sciences, granting permission to advance in France a Phase 3 clinical trial testing the cancer vaccine ... Read more

September 3, 2020September 3, 2020

FDA Approves Oral Chemotherapy Onureg for Newly Diagnosed AML Patients in Remission

News

The U.S. Food and Drug Administration has approved Onureg, an oral formulation of the chemotherapy azacitidine, as a maintenance treatment for adults with newly diagnosed acute myeloid leukemia (AML) who ... Read more

August 31, 2020August 31, 2020

Idhifa Combo Fails to Prolong Survival in Older Patients in Phase 3 Trial

News

Idhifa (enasidenib), given alongside best supportive care, failed to prolong overall survival of older adults with relapsed or refractory acute myeloid leukemia (AML) carrying a mutation in the IDH2 gene, ... Read more

August 27, 2020August 27, 2020

Venclexta Plus Vidaza Increases AML Survival, Study Shows

News

Adding Venclexta (venetoclax) to treatment with Vidaza (azacitidine) significantly prolongs survival in people with acute myeloid leukemia (AML) who have not been treated before, a new study demonstrates. The study, ... Read more